ARYA Sciences Acquisition Corp IV: Nasdaq/NYSE listing notice — Nasdaq adds annual meeting deficiency as separate delisting basis for ARYA; hearing April 25

ARYA Sciences Acquisition Corp IV

Additional Nasdaq delisting notice for failure to hold annual meeting within 12 months of FYE (Rule 5620(a)).
Hearing before Nasdaq Panel scheduled April 25, 2024 to consider both delisting bases.
Trading previously stayed; no assurance of continued listing on Nasdaq Capital Market.
Proposed business combination with Adagio Medical at risk if delisting occurs.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ARYA Sciences Acquisition Corp IV received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5620(a)

Exact text from the filing

March 26, 2024, ARYA received an additional and separate notice from the staff of the Listing Department of Nasdaq formally notifying ARYA that the deficiency under Nasdaq Listing Rule 5620(a) serves as an additional and separate basis for delisting and that the Panel will consider such additional matter at ARYA’s upcoming hearing (currently scheduled on April 25, 2024) to render a determination on ARYA’s continued listing on The Nasdaq Capital Market. There can be no assurance that ARYA will be able to satisfy Nasdaq’s continued listing requirements, obtain a favorable determination of the

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001140361-24-016371

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.